Development and Evaluation of Solidified Supersaturated SNEDDS Loaded with Triple Combination Therapy for Metabolic Syndrome
The present study aimed to develop and optimize solidified supersaturated self-nanoemulsifying drug delivery systems (SNEDDS) for the combined administration of antihypertensive, antihyperglycemic, and antihyperlipidemic drugs to enhance their solubility and dissolution during the treatment of metabolic syndrome. Various SNEDDS formulations were prepared and subjected to pharmaceutical assessment. The solubility of candesartan (CC), glibenclamide (GB), and rosuvastatin (RC) in SNEDDS and supersaturated SNEDDS formulations was evaluated. The optimized formulation was solidified using Syloid adsorbent at different ratios. Pharmaceutical characterization of the formulations included particle size, zeta potential, in-vitro dissolution, PXRD, FTIR, and SEM analysis.
The prepared optimized formulation (F6) was able to form homogeneous nanoemulsion droplets without phase separation, which is composed of Tween 20: PEG-400: Capmul MCM (4: 3: 3). It was mixed with 5% PVP-K30 to prepare a supersaturated liquid SNEDDS formulation (F9). In addition, it was found that the addition of PVP-K30 significantly increased solubility CC and GB from 20.46 ± 0.48 and 6.73 ± 0.05 to 27.67 ± 1.72 and 9.45 ± 0.32 mg/g, respectively. In-vitro dissolution study revealed that liquid and solid SNEDD formulations remarkably improved the dissolution rates of CC, GB, and RC compared to pure drugs. XRPD and FTIR analysis revealed that all drugs present in an amorphous state within prepared solidified supersaturated SNEDDS formulation.
SEM images showed that liquid SNEDDS formulation was successfully adsorbed on the surface of Syloid. Overall, optimized F9 and solidified supersaturated SNEDDS formulations showed superior performance in enhancing drug solubility and dissolution rate. The present study revealed that the proposed triple combination therapy of metabolic syndrome holds a promising strategy during the treatment of metabolic syndrome. Further in-vivo studies are required to evaluate the therapeutic efficacy of prepared solidified supersaturated SNEDDS formulation.
Read more here
Materials
Candesartan cilexetil and Glibenclamide were generously provided by Riyadh Pharma (Riyadh, Saudi Arabia) and SPIMACO (Qassim, KSA), respectively. Rosuvastatin calcium was acquired from Beijing Mesochem Technol-ogy Co., Ltd. (Beijing, China). Kolliphor-EL (K-EL, sur-factant), Kollidon® K30 (PVP-K30), and Kollisolv PEG 400 (PEG-400, co-surfactant) were acquired from BASF (Ludwigshafen, Germany). Tween-20 (T-20, surfactant) was supplied by BDH (England). Span-80 (S-80, co-surfactant) was purchased from Merck (Darmstadt, Germany). Capmul MCM (CMCM, oil) was obtained from Abitec Corporation (Janesville, USA). Oleic acid (OA, oil) was acquired from Avonchem (Cheshire, UK).
Sherif, A., Alshora, D.H., Ibrahim, M.A. et al. Development and Evaluation of Solidified Supersaturated SNEDDS Loaded with Triple Combination Therapy for Metabolic Syndrome. AAPS PharmSciTech 25, 209 (2024). https://doi.org/10.1208/s12249-024-02928-1
Read also our introduction article:
CPHI Milan 2024 – with a focus on excipients
